Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Misfolded α-synuclein spreads along anatomically connected areas through the brain, prompting progressive neurodegeneration of the nigrostriatal pathway in Parkinson's disease. To investigate the impact of early stage seeding and spreading of misfolded α-synuclein along with the nigrostriatal pathway, we studied the pathophysiologic effect induced by a single acute α-synuclein preformed fibrils (PFFs) inoculation into the midbrain. Further, to model the progressive vulnerability that characterizes the dopamine (DA) neuron life span, we used two cohorts of mice with different ages: 2-month-old (young) and 5-month-old (adult) mice. Two months after α-synuclein PFFs injection, we found that striatal DA release decreased exclusively in adult mice. Adult DA neurons showed an increased level of pathology spreading along with the nigrostriatal pathway accompanied with a lower volume of α-synuclein deposition in the midbrain, impaired neurotransmission, rigid DA terminal composition, and less microglial reactivity compared with young neurons. Notably, preserved DA release and increased microglial coverage in the PFFs-seeded hemisphere coexist with decreased large-sized terminal density in young DA neurons. This suggests the presence of a targeted pruning mechanism that limits the detrimental effect of α-synuclein early spreading. This study suggests that the impact of the pathophysiology caused by misfolded α-synuclein spreading along the nigrostriatal pathway depends on the age of the DA network, reducing striatal DA release specifically in adult mice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877754PMC
http://dx.doi.org/10.1111/bpa.13036DOI Listing

Publication Analysis

Top Keywords

nigrostriatal pathway
16
spreading nigrostriatal
12
misfolded α-synuclein
12
adult mice
12
α-synuclein spreading
8
pathway depends
8
striatal release
8
young neurons
8
α-synuclein
7
spreading
5

Similar Publications

Animal models of the pathology of Parkinson's disease (PD) have provided most of the treatments to date, but the disease is restricted to human patients. In vitro models using human pluripotent stem cells (hPSCs)-derived neural organoids have provided improved access to study PD etiology. This study established a method to generate human striatal-midbrain assembloids (hSMAs) from hPSCs for modeling alpha-synuclein (α-syn) propagation and recapitulating basal ganglia circuits, including nigrostriatal and striatonigral pathways.

View Article and Find Full Text PDF

Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies.

Neural Regen Res

August 2025

División de Neurociencias, Clínica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico.

The selective vulnerability of nigrostriatal dopaminergic neurons is a hallmark of Parkinson's disease and underlies its progressive motor decline. These neurons are uniquely susceptible to degeneration due to their extensive axonal arborization, high energy demands, sustained pacemaking activity, and cytosolic dopamine metabolism, which collectively promote oxidative stress and mitochondrial dysfunction. Advances in single-nucleus RNA sequencing and spatial transcriptomics have revealed transcriptionally distinct dopaminergic subtypes within the human substantia nigra pars compacta, such as AGTR1 + /SOX6 + and RIT2 + populations, which exhibit subtype-specific transcriptional stress signatures and are preferentially lost in Parkinson's disease.

View Article and Find Full Text PDF

Metabolic network remodeling and AI-driven precision diagnostics in geriatric Parkinson's disease: Advances in multimodal imaging.

Arch Gerontol Geriatr

November 2025

Xinjiang Medical University,No.567, Shangde North Road, Shuimogou District,Urumqi City, Xinjiang Uygur Autonomous Region, Urumchi 830000, PR China; The Second Affiliated Hospital of Xinjiang Medical University, No. 38, North Second Lane, Nanhu East Road, Urumqi, Xinjiang Uygur Autonomous Region, Uru

Research on the pathological mechanisms of Parkinson's disease (PD) reveals a significant association between nigrostriatal dopaminergic neuron degeneration and abnormal metabolic networks. However, the substantial increase in clinical heterogeneity complicates early diagnosis and subtyping. Significant progress has been made in recent years through multimodal neuroimaging studies.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive neurodegeneration of dopaminergic neurons (DNs) in the substantia nigra (SN). PD neuropathology is mainly related to inflammation, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum (ER) stress. The underlying causes for the progression of PD are linked to the uncontrolled activation of different signaling pathways, such as the renin-angiotensin system (RAS), which is highly expressed in the nigrostriatal pathway.

View Article and Find Full Text PDF

Motor symptoms traditionally characterise Parkinson's disease (PD), but cognitive dysfunctions have recently emerged as significant non-motor features. While dopamine deficiency in the substantia nigra primarily causes PD, recent evidence indicates disruptions in neurochemical pathways beyond the nigrostriatal system also contribute to cognitive dysfunction. This preclinical study examines the roles of dopamine and acetylcholine (ACh) within the hippocampus and prefrontal cortex (PFC), assessing how their combined reduction manifests as neurochemical alterations in brain regions relevant to cognitive function in PD.

View Article and Find Full Text PDF